Health Care • Other Pharmaceuticals
$12.93 ▼ -0.45
(-3.36%)
MKT CAP: $1.36B • VOL: 1.65M
52W L $8 52W H $20
HLF // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $5.04B | $4.99B | $5.06B |
| YoY Revenue Growth % | +0.9% | -1.4% | — |
| Gross Profit | $3.92B | $3.89B | — |
| Gross Margin % | 77.9% | 77.9% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $481.0M | $385.9M | $356.4M |
| Operating Margin % | 9.5% | 7.7% | 7.0% |
| Net Income (GAAP) | $228.3M | $254.3M | $142.2M |
| EBITDA (Normalized) | $545.3M | $483.5M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $333.3M | $285.4M | $357.5M |
| Capital Expenditures (CapEx) | $80.4M | $122.0M | — |
| Free Cash Flow (FCF) | $252.9M | $163.4M | $357.5M |
| FCF Margin % | 5.0% | 3.3% | 7.1% |
| Return on Invested Capital (ROIC %) | 34.4% | 40.1% | — |
| Cash & Short-Term Equivalents | $353.1M | $415.3M | — |
| Total Debt (Short + Long Term) | $1.97B | $1.98B | — |
| Total Stockholders' Equity | -$515.1M | -$801.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR HLF.